Adopting a strategy that lives up to the tagline ‘Reset, Resurgent’ that its investor presentations begins with, Strides Pharma Science Ltd. plans to repurpose some existing medicines for COVID-19 while counting on new products to fill the gap in revenues left by ranitidine after its withdrawal from the US market this April post a request by the US Food and Drug Administration (FDA).
Strides Optimistic On Prospects Of Antiviral Portfolio For COVID-19
Favipiravir Bioequivalence Studies To Begin In India
Optimistic about the potential of repurposing its antiviral portfolio, Strides plans to soon begin bioequivalence studies for favipiravir, a molecule that has found favor as a COVID-19 therapy in a few countries. It also aims to introduce new products to fill the gap left by the withdrawal of ranitidine from the US market.
More from Business
• By
Public Company Edition: Stock valuations are falling due to political, economic and regulatory uncertainty, resulting in fewer large public offerings, more alternative financings and cost cuts. Carisma, Tenaya, BioAtla, Arbutus, Nkarta, Alector and Adaptimmune announced layoffs.
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.